Synthelis

Synthelis is a service provider (CRO) for recombinant protein production using a proprietary cell-free expression system. Synthelis technology and know-how address difficult-to-express proteins with standard cell-based expression systems. The major proteins concerned are membrane proteins as  well as cytotoxic proteins. 

The Synthelis offering is divided up into the following areas:

- Expression feasibility phase

- Activity validation phase (using SPR, patch-clamp…)

- Optimization phase to improve activity levels or purity rates

- Scale-up of production (several milligrams / month)Synthelis is also developing new approaches for protein therapy and vaccine development based on membrane protein delivery by liposomal vectors.